Arax Advisory Partners’s Ocular Therapeutix OCUL Stock Holding History

Arax Advisory Partners’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.26K	Buy	503 +125	+33%	+$1.19K	﹤0.01%	2864
2025 Q4	$4.59K	Buy	+378	New	+$4.59K	﹤0.01%	2901
2025 Q3	–	Sell	-87	Closed	-$808	–	4080
2025 Q2	$808	Hold	87	–	–	﹤0.01%	2848
2025 Q1	$638	Sell	87 -187	-68%	-$1.44K	﹤0.01%	2480
2024 Q4	$2.34K	Hold	274	–	–	﹤0.01%	1972
2024 Q3	$2.38K	Hold	274	–	–	﹤0.01%	1998
2024 Q2	$1.88K	Buy	+274	New	+$1.69K	﹤0.01%	1987

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Arax Advisory Partners's OCUL Position: Q1 2026 in Review

Arax Advisory Partners increased its Ocular Therapeutix (OCUL) stake by 33% in Q1 2026, buying an estimated $1.19K and bringing the position to 503 shares worth $4.26K. The position accounts for ﹤0.01% of the portfolio, ranked #2864.

Arax Advisory Partners first reported a position in OCUL in Q2 2024 and has held it in 7 quarters since. The position peaked at $4.59K in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Arax Advisory Partners held 503 shares of Ocular Therapeutix worth $4.26K as of Q1 2026.
Arax Advisory Partners bought 125 Ocular Therapeutix shares in Q1 2026, an estimated $1.19K.
Ocular Therapeutix made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #2864 holding.
Arax Advisory Partners first reported a position in Ocular Therapeutix in Q2 2024 and has held it in 7 quarters since.
Arax Advisory Partners's Ocular Therapeutix position peaked at $4.59K in Q4 2025.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.